Northern Trust’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-571,093
| Closed | -$5.48M | – | 4553 |
|
|
2024
Q4 | $5.48M | Buy |
571,093
+5,706
| +1% | +$29.8K | ﹤0.01% | 2457 |
|
|
2024
Q3 | $1.62M | Buy |
565,387
+19,091
| +3% | +$59.1K | ﹤0.01% | 3123 |
|
|
2024
Q2 | $1.6M | Sell |
546,296
-12,099
| -2% | -$33.1K | ﹤0.01% | 3023 |
|
|
2024
Q1 | $1.78M | Buy |
558,395
+3,859
| +0.7% | +$12.9K | ﹤0.01% | 3023 |
|
|
2023
Q4 | $1.86M | Buy |
554,536
+11,406
| +2% | +$29.4K | ﹤0.01% | 3032 |
|
|
2023
Q3 | $1.29M | Buy |
543,130
+33,171
| +7% | +$69.5K | ﹤0.01% | 3181 |
|
|
2023
Q2 | $898K | Buy |
509,959
+406,192
| +391% | +$1.04M | ﹤0.01% | 3398 |
|
|
2023
Q1 | $320K | Buy |
103,767
+18,301
| +21% | +$110K | ﹤0.01% | 3641 |
|
|
2022
Q4 | $453K | Buy |
85,466
+20,298
| +31% | +$92.8K | ﹤0.01% | 3540 |
|
|
2022
Q3 | $231K | Buy |
65,168
+14,922
| +30% | +$49.3K | ﹤0.01% | 3817 |
|
|
2022
Q2 | $129K | Sell |
50,246
-189,043
| -79% | -$526K | ﹤0.01% | 4079 |
|
|
2022
Q1 | $1.07M | Sell |
239,289
-12,504
| -5% | -$56.4K | ﹤0.01% | 3387 |
|
|
2021
Q4 | $1.72M | Sell |
251,793
-5,268
| -2% | -$35.9K | ﹤0.01% | 3299 |
|
|
2021
Q3 | $1.87M | Buy |
257,061
+11,992
| +5% | +$103K | ﹤0.01% | 3323 |
|
|
2021
Q2 | $2.46M | Buy |
245,069
+79,644
| +48% | +$713K | ﹤0.01% | 3266 |
|
|
2021
Q1 | $1.58M | Buy |
165,425
+3,230
| +2% | +$31.7K | ﹤0.01% | 3371 |
|
|
2020
Q4 | $1.78M | Sell |
162,195
-5,355
| -3% | -$56.5K | ﹤0.01% | 3246 |
|
|
2020
Q3 | $1.49M | Buy |
+167,550
| New | +$1.91M | ﹤0.01% | 3202 |
|
Other funds holding PSTX
Northern Trust's PSTX Position: Q1 2025 in Review
Northern Trust sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 571,093 shares — an estimated $5.48M sold.
Northern Trust first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $5.48M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Northern Trust reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Northern Trust sold 571,093 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $5.48M.
- Northern Trust first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Northern Trust's Poseida Therapeutics, Inc. Common Stock position peaked at $5.48M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Northern Trust's 13F filing for Q1 2025, filed 13 May 2025.